×

CNBC Utilities Page Drugs

  • Reddy's, Allergan Plc's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV. The lawsuits allege that these companies have infringed a patent that relates to an oral film containing buprenorphine and naloxone, the key constituents of Suboxone, the London- listed drugmaker said in a...

  • Sept 13- As generic drug manufacturers are. Last week, Allergan announced it would transfer the patent rights to its Restasis dry-eye treatment to the Saint Regis Mohawk Tribe, which will license them back to the company in exchange for ongoing payments. But Richard Torczon, a lawyer for generic drug company Mylan.

  • Halozyme to license its drug delivery tech to Bristol-Myers and Roche

    Halozyme CEO Dr. Helen Torley speaks with CNBC's Meg Tirrell about the company using technology that makes it easier for patients to take medicine.

  • Americans are unwittingly contributing to the opioid epidemic by leaving a massive supply of unused painkillers in circulation.

  • Sept 7- New Mexico on Thursday sued eight opioid manufacturers and wholesale distributors, becoming the latest state or local government to file a lawsuit seeking to hold corporations accountable for a national drug addiction epidemic. New Mexico Attorney General Hector Balderas accused Purdue Pharma LP, Johnson& Johnson, Allergan Plc, Endo International...

  • Sept 7- New Mexico on Thursday sued eight opioid manufacturers and wholesale distributors, becoming the latest state or local government to file a lawsuit seeking to hold corporations accountable for a national drug addiction epidemic. New Mexico Attorney General Hector Balderas accused Purdue Pharma LP, Johnson& Johnson, Allergan Plc, Endo International...

  • MIDLAND, Texas, Sept 7- When Joe Forsythe returned to the West Texas oilfields last year after a stint in a drug rehab facility, he figured he had beaten his addiction to methamphetamine. Drug use is a significant factor in workplace injuries and crimes involving oilfield workers, according to drug counselors, hospital and police officials and court records in...

  • BOSTON, Sept 6- Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report was the first by McCaskill, the ranking Democrat on the U.S. Senate Homeland Security and Governmental Affairs...

  • BOSTON, Sept 6- Insys Therapeutics Inc sought to manipulate the process to gain insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report related to the national opioid addiction crisis released on Wednesday. The report was the first by McCaskill, the ranking Democrat on the U.S....

  • Doug Ingram, CEO, Sarepta

    Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy.

  • Jack Willis, center, Nolan Willis, right, and Max LeClaire,bottom, are all afflicted with Duchenne muscular dystrophy. They attended the opening for Sarepta Therapeutics new global headquarters in Cambridge on Monday morning, June 2, 2014.

    Sarepta Therapeutics reports positive results from a clinical trial of an experimental medicine for Duchenne muscular dystrophy.

  • Lung xray

    Insmed, maker of the new drug Alis, said it will use the proceeds of the stock offering to push the medication to market.

  • Insmed soars on positive lung drug study results

    CNBC's Meg Tirrell reports the latest on shares of Insmed and how the stock is more than doubling today.

  • Opioids

    CNBC's Ylan Mui reports on the opioid epidemic impacting the labor market.

  • *FTSE 100 ends up 0.1 percent. The FTSE 100 ended up 0.1 percent, while the mid cap FTSE 250 index was held back with a 0.1 percent retreat due to the collapse of Indivior's shares. Miners, which had already helped the FTSE stay in positive territory in the previous session, were up with Glencore rising 2.1 percent, Antofagasta 2.2 percent and Rio Tinto 0.3 percent.

  • *FTSE 100 up 0.4 percent. The FTSE 100 rose 0.4 percent by 0837 GMT while the wider FTSE 250 was held back with a 0.2 percent retreat due to the collapse of Indivior's shares. Miners, which had already helped the FTSE stay in positive territory in the previous session, were up with Glencore rising 1.4 percent, Antofagasta 1.2 percent and Rio Tinto 0.4 percent.

  • Sept 1- Shares in Indivior plunged 40 percent on Friday after it said a U.S. court ruling could lead to a generic rival to its treatment for opioid addiction that generates 80 percent of the London- listed drug maker's revenues. Indivior has said it would not be able to rely on patents to prevent Indian firm Dr.Reddy' s from making and marketing a generic alternative...

  • LONDON, Sept 1- European shares started September on a firm footing on Friday after three months of losses as financials rose and an update from Vivendi boosted media stocks. Germany' DAX gained 0.5 percent and Britain's FTSE 100 rose 0.2 percent, though a near-40 percent slump in Indivior's shares put pressure on the FTSE 250 which retreated 0.2 percent.

  • LONDON, Sept 1- European shares rose early on Friday, starting September on a firm footing after three months of losses as financials rose and an update from Vivendi boosted media stocks, though a record plunge in pharma firm Indivior weighed on British mid caps. Germany' DAX gained 0.3 percent and Britain's FTSE 100 rose 0.2 percent, though a 35 percent slump in...

  • Reddy's from making and marketing a generic alternative to Suboxone Film in the United States, unless the court's ruling was reversed on appeal. The firm said the average market share of Suboxone Film in the United States was 61 percent in 2016, and accounted for 80 percent of Indivior's total revenues last year. Shares in Indivior, which was spun off from...